Molecular Targeting Technologies, Inc.
Translating radiopharmaceuticals into tomorrow’s medicine
Molecular Targeting Technologies, Inc. (MTTI), a privately held company, focuses on radiopharmaceuticals for treatment and diagnosis of rare diseases.
Our therapeutics, supported by published data and ongoing Phase I clinical trials, include:
- EBTATE (177Lu-EB-DOTA-TATE), a neuroendocrine tumor therapy (NET). EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing PRRTs. Treatments using either 1.85 or 3.7 GBq EBTATE in NET patients were well tolerated and more
- 131I-SapC-DOPS, a nanovesicle for glioblastoma multiforme (GBM), readily crosses the blood brain barrier delivering a dual killing effect. Preclinical studies demonstrated that the 131I-SapC-DOPS improves survival by 43% compared with SapC-DOPS alone.
Our diagnostics include:
- TDURA (99mTc-duramycin), for systemic inflammatory response syndrome (SIRS) and organ transplant rejection applications. A clinical study for early detection of tumor response to treatment will begin in 4Q 2019.
- 18F-glucaric acid is being developed for detecting stroke and acute MI. 99mTc-glucarate, was effective for MI detection in a phase II clinical trial.
Brands: EBTATE ( Lu-177-EB-TATE); TDURA (Tc-99m Duramycin); FGA ( F-18 glucaric acid); I-131-SapC-DOPS